TCR² Therapeutics competitors

Experienced public company CEO determined to leave the world a healthier place than when he arrived by developing new treatments for serious diseases and conditions.

Mr. Onsi has served as our Chief Financial Officer, Treasurer and Secretary since our inception in 2011. Mr. Onsi has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCare Ventures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.

Adrian (Ad) Rawcliffe is a Chief Executive Officer at Adaptimmune, Senior VP:Worldwide Bus Dev at GSK, and Board Member at WaVe Life Sciences Pte Ltd and is based in Philadelphia, Pennsylvania. He has worked as Chartered Accountant at Pricewaterhouse Coopers (PwC), President/Managing Partner at Sr One, and Chief Financial Officer at Adaptimmune Therapeutics Plc. Adrian (Ad) studied at Durham University between 1990 and 1993 and Masters of Awkward.

David is an entrepreneur and angel investor who has held operating roles at six startups and invested in 70 companies. He was most recently the Chief Executive Officer of Gradifi, which was acquired by E*TRADE. Previously, he was Entrepreneur-in-Residence at Harvard Business School and Director of the Babson Summer Venture Program.For more info, see www.davidchang.mePAST EXPERIENCEDavid has a successful track record in hands-on roles at both direct-to-consumer and enterprise companies, six of which were acquired or IPO’d. He previously led the PayPal Boston office and co-founded the Start Tank innovation space and the Where Angel Fund. Before WHERE’s acquisition by PayPal in April 2011, he held the role of VP of Product, which included strategy and corporate development.Earlier in his career, on the consumer side, David was Director of New Products at TripAdvisor where he launched new features to meet consumers’ needs. He was VP of Marketing and Co-founder of SnapMyLife where he led product and marketing efforts. On the enterprise side, David was Director of Product Marketing at m-Qube, a pioneer in the mobile content space. He was Senior Product Manager at edocs and was a VP of Technology at Goldman Sachs.As a leader in the entrepreneurship community, David holds several advisor/board memberships. He is on the board at MITX, an advisor at Harvard Ventures, Nanigans, CO Everywhere, OpenFrame, and Linkwell Health. He has made 70 angel investments in startups such as Crashlytics, clypd, Amino, Logz, Cuseum, CarePort Health, Dashfire, Mogul, Uncharted Play, through the Where Angel Fund and TBD Angels. David is a frequent speaker on the topics of startups, fundraising, and the Boston tech ecosystem, and he actively mentors students and founders. Awards include Boston Business Journal's Power 50: Most Influential Bostonians, BostInno’s 50 on Fire: Education Winner / Investment Winner / Tech Finalist, and Finalist for NEVY Angel of the Year.ADVISOR ROLESBoard Member at MITX, FeelterAdvisory Board Member at Inrupt, Harvard Ventures, Nanigans, CO Everywhere, Campseekers, SharalikeAdvisor & Mentor at MassChallengeMentor at TechStarsANGEL INVESTMENTS70 angel investments in startups such as Crashlytics, clypd, Amino, CarePort Health, WEVO, Cuseum, Dashfire, Mogul, Uncharted Play, xPeerient, and through the Where Angel Fund

Rami joined Arcellx in 2021 and serves as the Chairman and Chief Executive Officer. Most recently, Rami served as President and CEO of Nevro, where he joined in 2012. Under his leadership, Nevro grew from a small private company to a public company approaching $400m in revenue and a leader in neuromodulation. Prior to Nevro, Rami was an investor with Johnson & Johnson Development Corporation (JJDC), where he led several investments including Nevro’s Series B Financing and served on the Board of Directors of several private companies including Nevro’s. Prior to joining JJDC, Rami was a Design Engineer for Advanced Neuromodulation Systems, Inc. where he led firmware design and development on several implantable spinal cord stimulators. Rami earned recognition as an EY Entrepreneur of the Year, as one of the top CEOs in the U.S. and as one of the top CEOs for women and diversity. He is a recipient of the Bill Campbell award by Watermark for his influence, impact, and advocacy in promoting women and women’s issues. Rami received a MBA from the Wharton School of the University of Pennsylvania and holds a BS in Electrical and Computer Engineering from Rutgers University School of Engineering.